Exact Mass: 524.290275
Exact Mass Matches: 524.290275
Found 500 metabolites which its exact mass value is equals to given mass value 524.290275
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
VPGPR Enterostatin
C23H40N8O6 (524.3070660000001)
Enterostatin VPGPR (Val-Pro-Gly-Pro-Arg) is a pentapeptide released from procolipase during fat digestion. In addition to the pancreas, enterostatin-immunoreactive cells are also present in the antrum and proximal small intestine. Enterostatin selectively reduces fat intake, decreases insulin secretion, and also increases energy expenditure by activating brown adipose tissue during high-fat feeding. Enterostatins are pentapeptides derived from the NH2-terminus of procolipase after tryptic cleavage and belong to the family of gut-brain peptides. Enterostatin is generated by the action of trypsin on procolipase in the intestinal lumen. Its structure is highly conserved in evolution, with an amino acid sequence of XPXPR. Three enterostatin sequences, Val-Pro-Asp-Pro-Arg (VPDPR), Val-Pro-Gly-Pro-Arg (VPGPR), and Ala-Pro-Gly-Pro-Arg (APGPR), have been studied extensively and shown to be almost equally effective in their ability to decrease dietary fat preference. Enterostatins are selective inhibitors of appetite, particularly of fat intake. Hyperenterostatinemia in obesity is probably secondary to enterostatin resistance; therefore, the regulatory system is producing more enterostatin to counteract the resistance. This is very similar to hyperinsulinemia and hyperleptinemia in obesity. The diminution in the meal-induced secretion of enterostatin in obesity suggests a delay in the appearance of satiety, leading to increased caloric intake. In rats enterostatin decreases body weight by decreasing fat-calorie intake and increasing the sympathetic firing rate of the nerves in interscapular brown adipose tissue. Enterostatin levels are elevated in the plasma of obese women, and enterostatin secretion is diminished after satiety. Oral administration of enterostatin, however, has no effect on food intake, energy expenditure, or body weight in subjects with a preference for a high-fat diet experiencing a negative energy and fat balance, and the physiology of enterostatin in humans remains to be defined. (PMID: 10084574, 9526102, 8886249) [HMDB] Enterostatin VPGPR (Val-Pro-Gly-Pro-Arg) is a pentapeptide released from procolipase during fat digestion. In addition to the pancreas, enterostatin-immunoreactive cells are also present in the antrum and proximal small intestine. Enterostatin selectively reduces fat intake, decreases insulin secretion, and also increases energy expenditure by activating brown adipose tissue during high-fat feeding. Enterostatins are pentapeptides derived from the NH2-terminus of procolipase after tryptic cleavage and belong to the family of gut-brain peptides. Enterostatin is generated by the action of trypsin on procolipase in the intestinal lumen. Its structure is highly conserved in evolution, with an amino acid sequence of XPXPR. Three enterostatin sequences, Val-Pro-Asp-Pro-Arg (VPDPR), Val-Pro-Gly-Pro-Arg (VPGPR), and Ala-Pro-Gly-Pro-Arg (APGPR), have been studied extensively and shown to be almost equally effective in their ability to decrease dietary fat preference. Enterostatins are selective inhibitors of appetite, particularly of fat intake. Hyperenterostatinemia in obesity is probably secondary to enterostatin resistance; therefore, the regulatory system is producing more enterostatin to counteract the resistance. This is very similar to hyperinsulinemia and hyperleptinemia in obesity. The diminution in the meal-induced secretion of enterostatin in obesity suggests a delay in the appearance of satiety, leading to increased caloric intake. In rats enterostatin decreases body weight by decreasing fat-calorie intake and increasing the sympathetic firing rate of the nerves in interscapular brown adipose tissue. Enterostatin levels are elevated in the plasma of obese women, and enterostatin secretion is diminished after satiety. Oral administration of enterostatin, however, has no effect on food intake, energy expenditure, or body weight in subjects with a preference for a high-fat diet experiencing a negative energy and fat balance, and the physiology of enterostatin in humans remains to be defined. (PMID: 10084574, 9526102, 8886249).
Fedratinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EJ - Janus-associated kinase (jak) inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C172200 - JAK Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C125450 - JAK2 Inhibitor
Methyl (2-((R)-(3-chlorophenyl)((R)-1-(((S)-2-(methylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propyl)carbamoyl)piperidin-3-yl)methoxy)ethyl)carbamate
L-Proline, 1-(N2-(1-carboxy-3-phenylpropyl)-N6-((4-hydroxyphenyl)iminomethyl)-L-lysyl)-, (S)-
Falecalcitriol
C27H38F6O3 (524.2724989999999)
Sucrose laurate
Sucrose monolaurate
Sucrose, 1-laurate
Okaramine C
An indole alkaloid isolated from Penicillium simplicissimum. It exhibits insecticidal activity.
(3E,7E,11E,15E)-5,9,13,17,18-pentahydroxy-4,6,8,10-tetramethyl-2-[(E)-2-methylbut-2-enyl]nonadeca-3,7,11,15-tetraenedioic acid
2beta,3alpha,14alpha,16-Tetraacetoxy-15beta-hydroxy-ent-pimarane
(1R,3aS,5R,10aS,11aS,13aR)-1,2,3,3a,3b,4,5,5a,6,12,13,13a-dodecahydro-3a,6,6,13a-tetramethyl-1-[(1S)-1-((2S)-5-methyl-6-oxo-3,6-dihydro-2H-pyran-2-yl)ethyl]-8-oxo-8H-cyclopenta[5,6]cyclopropa[1,8a]naphtho[2,1-c]oxepin-5-yl acetate|schisanbilactone A
2alpha-acetyloxy-4beta-hydroxy-6alpha-angeloyloxy-10beta-cinnamoyloxydauc-8-ene|2??-Acetoxy-4??-hydroxy-6??-angeloyloxy-10??-cinnamoyloxy-dauc-8-ene
16-acetoxy-22alpha-hydroxy-29-nor-24-methylcycloart-1,4, 24(24a)-trien-3,23-dion-3,4-lactone|4-methylene-neomacrolactone
(21R,23S)-3,26-dioxo-21,23:23,26-diepoxylanosta-8,24-dien-21-yl acetate|omphalocarpoidone
24-acetoxy-18alpha-hydroxy-A(1)-norlupa-2,20(29)-diene-27,28-diolic acid 28-methyl ester 27,18alpha-lactone
13alpha-acetoxy-5-alpha-cinnamoyloxy-11(15-1)abeotaxa-4(20),11-diene-9alpha,10beta,15-triol
12alpha-chloro-2alpha,3beta,13beta,23-tetrahydroxyolean-28-oic acid-13-lactone
(1R*,2R*,3E,7R*,11R*,12S*)-2-O-acetyl-16-O-(3-hydroxy-3-methylglutaryl)-dolabella-3,8(17)-dien-2,7,16,18-tetrol
Ser Gln Tyr Lys
Valtrate hydrine B4
[3-methyl-1-[3-methyl-1-oxo-1-(2,3,4,5,6-pentahydroxyhexoxy)pentan-2-yl]oxy-1-oxopentan-2-yl] 2-hydroxy-3-methylpentanoate
C31H40O7_3,9-Diacetoxy-2,6,6,13-tetramethyl-12-oxotetracyclo[11.2.1.0~1,10~.0~2,7~]hexadec-8-yl benzoate
[3-methyl-1-[3-methyl-1-oxo-1-(2,3,4,5,6-pentahydroxyhexoxy)pentan-2-yl]oxy-1-oxopentan-2-yl] 2-hydroxy-3-methylpentanoate [IIN-based on: CCMSLIB00000846977]
[3-methyl-1-[3-methyl-1-oxo-1-(2,3,4,5,6-pentahydroxyhexoxy)pentan-2-yl]oxy-1-oxopentan-2-yl] 2-hydroxy-3-methylpentanoate [IIN-based: Match]
(3E,7E,11E,15E)-5,9,13,17,18-pentahydroxy-4,6,8,10-tetramethyl-2-[(E)-2-methylbut-2-enyl]nonadeca-3,7,11,15-tetraenedioic acid_minor
(3E,7E,11E,15E)-5,9,13,17,18-pentahydroxy-4,6,8,10-tetramethyl-2-[(E)-2-methylbut-2-enyl]nonadeca-3,7,11,15-tetraenedioic acid_major
Cys Phe Lys Lys
C24H40N6O5S (524.2780750000001)
Cys Lys Phe Lys
C24H40N6O5S (524.2780750000001)
Cys Lys Lys Phe
C24H40N6O5S (524.2780750000001)
Glu Ile Thr Tyr
Glu Ile Tyr Thr
Glu Leu Thr Tyr
Glu Leu Tyr Thr
Glu Thr Ile Tyr
Glu Thr Leu Tyr
Glu Thr Tyr Ile
Glu Thr Tyr Leu
Glu Tyr Ile Thr
Glu Tyr Leu Thr
Glu Tyr Thr Ile
Glu Tyr Thr Leu
Phe Cys Lys Lys
C24H40N6O5S (524.2780750000001)
Phe Phe Ile Val
Phe Phe Leu Val
Phe Phe Val Ile
Phe Phe Val Leu
Phe Ile Phe Val
Phe Ile Val Phe
Phe Lys Cys Lys
C24H40N6O5S (524.2780750000001)
Phe Lys Lys Cys
C24H40N6O5S (524.2780750000001)
Phe Leu Phe Val
Phe Leu Val Phe
Phe Pro Val Tyr
Phe Pro Tyr Val
Phe Val Phe Ile
Phe Val Phe Leu
Phe Val Ile Phe
Phe Val Leu Phe
Phe Val Pro Tyr
Phe Val Tyr Pro
Phe Tyr Pro Val
Phe Tyr Val Pro
Gly His Arg Arg
Gly Arg His Arg
Gly Arg Arg His
His Gly Arg Arg
His Ile Lys Gln
C23H40N8O6 (524.3070660000001)
His Ile Gln Lys
C23H40N8O6 (524.3070660000001)
His Ile Gln Gln
His Lys Ile Gln
C23H40N8O6 (524.3070660000001)
His Lys Leu Gln
C23H40N8O6 (524.3070660000001)
His Lys Gln Ile
C23H40N8O6 (524.3070660000001)
His Lys Gln Leu
C23H40N8O6 (524.3070660000001)
His Leu Lys Gln
C23H40N8O6 (524.3070660000001)
His Leu Gln Lys
C23H40N8O6 (524.3070660000001)
His Leu Gln Gln
His Asn Arg Val
His Asn Val Arg
His Gln Ile Lys
C23H40N8O6 (524.3070660000001)
His Gln Ile Gln
His Gln Lys Ile
C23H40N8O6 (524.3070660000001)
His Gln Lys Leu
C23H40N8O6 (524.3070660000001)
His Gln Leu Lys
C23H40N8O6 (524.3070660000001)
His Gln Leu Gln
His Gln Gln Ile
His Gln Gln Leu
His Arg Gly Arg
His Arg Asn Val
His Arg Arg Gly
His Arg Val Asn
His Val Asn Arg
His Val Arg Asn
Ile Glu Thr Tyr
Ile Glu Tyr Thr
Ile Phe Phe Val
Ile Phe Val Phe
Ile His Lys Gln
C23H40N8O6 (524.3070660000001)
Ile His Gln Lys
C23H40N8O6 (524.3070660000001)
Ile His Gln Gln
Ile Lys His Gln
C23H40N8O6 (524.3070660000001)
Ile Lys Gln His
C23H40N8O6 (524.3070660000001)
Ile Met Val Tyr
Ile Met Tyr Val
Ile Gln His Lys
C23H40N8O6 (524.3070660000001)
Ile Gln His Gln
Ile Gln Lys His
C23H40N8O6 (524.3070660000001)
Ile Gln Gln His
Ile Thr Glu Tyr
Ile Thr Tyr Glu
Ile Val Phe Phe
Ile Val Met Tyr
Ile Val Tyr Met
Ile Tyr Glu Thr
Ile Tyr Met Val
Ile Tyr Thr Glu
Ile Tyr Val Met
Lys Cys Phe Lys
C24H40N6O5S (524.2780750000001)
Lys Cys Lys Phe
C24H40N6O5S (524.2780750000001)
Lys Phe Cys Lys
C24H40N6O5S (524.2780750000001)
Lys Phe Lys Cys
C24H40N6O5S (524.2780750000001)
Lys His Ile Gln
C23H40N8O6 (524.3070660000001)
Lys His Leu Gln
C23H40N8O6 (524.3070660000001)
Lys His Gln Ile
C23H40N8O6 (524.3070660000001)
Lys His Gln Leu
C23H40N8O6 (524.3070660000001)
Lys Ile His Gln
C23H40N8O6 (524.3070660000001)
Lys Ile Gln His
C23H40N8O6 (524.3070660000001)
Lys Lys Cys Phe
C24H40N6O5S (524.2780750000001)
Lys Lys Phe Cys
C24H40N6O5S (524.2780750000001)
Lys Lys Ser Tyr
Lys Lys Tyr Ser
Lys Leu His Gln
C23H40N8O6 (524.3070660000001)
Lys Leu Gln His
C23H40N8O6 (524.3070660000001)
Lys Asn Thr Tyr
Lys Asn Tyr Thr
Lys Gln His Ile
C23H40N8O6 (524.3070660000001)
Lys Gln His Leu
C23H40N8O6 (524.3070660000001)
Lys Gln Ile His
C23H40N8O6 (524.3070660000001)
Lys Gln Leu His
C23H40N8O6 (524.3070660000001)
Lys Gln Ser Tyr
Lys Gln Tyr Ser
Lys Ser Lys Tyr
Lys Ser Gln Tyr
Lys Ser Tyr Lys
Lys Ser Tyr Gln
Lys Thr Asn Tyr
Lys Thr Tyr Asn
Lys Tyr Lys Ser
Lys Tyr Asn Thr
Lys Tyr Gln Ser
Lys Tyr Ser Lys
Lys Tyr Ser Gln
Lys Tyr Thr Asn
Leu Glu Thr Tyr
Leu Glu Tyr Thr
Leu Phe Phe Val
Leu Phe Val Phe
Leu His Lys Gln
C23H40N8O6 (524.3070660000001)
Leu His Gln Lys
C23H40N8O6 (524.3070660000001)
Leu His Gln Gln
Leu Lys His Gln
C23H40N8O6 (524.3070660000001)
Leu Lys Gln His
C23H40N8O6 (524.3070660000001)
Leu Met Val Tyr
Leu Met Tyr Val
Leu Gln His Lys
C23H40N8O6 (524.3070660000001)
Leu Gln His Gln
Leu Gln Lys His
C23H40N8O6 (524.3070660000001)
Leu Gln Gln His
Leu Thr Glu Tyr
Leu Thr Tyr Glu
Leu Val Phe Phe
Leu Val Met Tyr
Leu Val Tyr Met
Leu Tyr Glu Thr
Leu Tyr Met Val
Leu Tyr Thr Glu
Leu Tyr Val Met
Met Ile Val Tyr
Met Ile Tyr Val
Met Leu Val Tyr
Met Leu Tyr Val
Met Val Ile Tyr
Met Val Leu Tyr
Met Val Tyr Ile
Met Val Tyr Leu
Met Tyr Ile Val
Met Tyr Leu Val
Met Tyr Val Ile
Met Tyr Val Leu
Asn His Arg Val
Asn His Val Arg
Asn Lys Thr Tyr
Asn Lys Tyr Thr
Asn Arg His Val
Asn Arg Val His
Asn Thr Lys Tyr
Asn Thr Tyr Lys
Asn Val His Arg
Asn Val Arg His
Asn Tyr Lys Thr
Asn Tyr Thr Lys
Pro Phe Val Tyr
Pro Phe Tyr Val
Pro Pro Arg Arg
Pro Arg Pro Arg
Pro Arg Arg Pro
Pro Val Phe Tyr
Pro Val Tyr Phe
Pro Tyr Phe Val
Pro Tyr Val Phe
Gln His Ile Lys
C23H40N8O6 (524.3070660000001)
Gln His Ile Gln
Gln His Lys Ile
C23H40N8O6 (524.3070660000001)
Gln His Lys Leu
C23H40N8O6 (524.3070660000001)
Gln His Leu Lys
C23H40N8O6 (524.3070660000001)
Gln His Leu Gln
Gln His Gln Ile
Gln His Gln Leu
Gln Ile His Lys
C23H40N8O6 (524.3070660000001)
Gln Ile His Gln
Gln Ile Lys His
C23H40N8O6 (524.3070660000001)
Gln Ile Gln His
Gln Lys His Ile
C23H40N8O6 (524.3070660000001)
Gln Lys His Leu
C23H40N8O6 (524.3070660000001)
Gln Lys Ile His
C23H40N8O6 (524.3070660000001)
Gln Lys Leu His
C23H40N8O6 (524.3070660000001)
Gln Lys Ser Tyr
Gln Lys Tyr Ser
Gln Leu His Lys
C23H40N8O6 (524.3070660000001)
Gln Leu His Gln
Gln Leu Lys His
C23H40N8O6 (524.3070660000001)
Gln Leu Gln His
Gln Gln His Ile
Gln Gln His Leu
Gln Gln Ile His
Gln Gln Leu His
Gln Ser Lys Tyr
Gln Ser Tyr Lys
Gln Tyr Lys Ser
Gln Tyr Ser Lys
Arg Gly His Arg
Arg Gly Arg His
Arg His Gly Arg
Arg His Asn Val
Arg His Arg Gly
Arg His Val Asn
Arg Asn His Val
Arg Asn Val His
Arg Pro Pro Arg
Arg Pro Arg Pro
Arg Arg Gly His
Arg Arg His Gly
Arg Arg Pro Pro
Arg Val His Asn
Arg Val Asn His
Ser Lys Lys Tyr
Ser Lys Gln Tyr
Ser Lys Tyr Lys
Ser Lys Tyr Gln
Ser Gln Lys Tyr
Ser Tyr Lys Lys
Ser Tyr Lys Gln
Ser Tyr Gln Lys
Thr Glu Ile Tyr
Thr Glu Leu Tyr
Thr Glu Tyr Ile
Thr Glu Tyr Leu
Thr Ile Glu Tyr
Thr Lys Asn Tyr
Thr Lys Tyr Asn
Thr Asn Lys Tyr
Thr Asn Tyr Lys
Thr Tyr Lys Asn
Thr Tyr Asn Lys
Val Phe Phe Ile
Val Phe Phe Leu
Val Phe Ile Phe
Val Phe Leu Phe
Val Phe Pro Tyr
Val Phe Tyr Pro
Val His Asn Arg
Val His Arg Asn
Val Ile Phe Phe
Val Ile Met Tyr
Val Ile Tyr Met
Val Leu Phe Phe
Val Leu Met Tyr
Val Leu Tyr Met
Val Met Ile Tyr
Val Met Leu Tyr
Val Met Tyr Ile
Val Met Tyr Leu
Val Asn His Arg
Val Asn Arg His
Val Pro Phe Tyr
Val Pro Tyr Phe
Val Arg His Asn
Val Arg Asn His
Val Tyr Phe Pro
Val Tyr Ile Met
Val Tyr Leu Met
Val Tyr Met Ile
Val Tyr Met Leu
Val Tyr Pro Phe
Tyr Phe Pro Val
Tyr Phe Val Pro
Tyr Ile Met Val
Tyr Ile Val Met
Tyr Lys Lys Ser
Tyr Lys Asn Thr
Tyr Lys Gln Ser
Tyr Lys Ser Lys
Tyr Lys Ser Gln
Tyr Lys Thr Asn
Tyr Leu Met Val
Tyr Leu Val Met
Tyr Met Ile Val
Tyr Met Leu Val
Tyr Met Val Ile
Tyr Met Val Leu
Tyr Asn Lys Thr
Tyr Asn Thr Lys
Tyr Pro Phe Val
Tyr Pro Val Phe
Tyr Gln Lys Ser
Tyr Gln Ser Lys
Tyr Ser Lys Lys
Tyr Ser Lys Gln
Tyr Ser Gln Lys
Tyr Thr Lys Asn
Tyr Thr Asn Lys
Tyr Val Phe Pro
Tyr Val Ile Met
Tyr Val Leu Met
Tyr Val Met Ile
Tyr Val Met Leu
Tyr Val Pro Phe
(5Z,7E)-(1S,3R)-26,26,26,27,27,27-hexafluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
C27H38F6O3 (524.2724989999999)
(5Z,7E)-(1S,3R)-26,26,26,27,27,27-hexafluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
C27H38F6O3 (524.2724989999999)
VPGPR Enterostatin
C23H40N8O6 (524.3070660000001)
Synthetic Ligand of FKBP
3,9-Diacetoxy-2,6,6,13-tetramethyl-12-oxotetracyclo[11.2.1.01,10.02,7]hexadec-8-yl benzoate
26,26,26,27,27,27-hexafluoro-1alpha,24-dihydroxyvitamin D3
26,26,26,27,27,27-hexafluoro-1alpha,25-dihydroxyvitamin D3
8-(2,3-dihydro-1H-inden-5-yl)-N-methoxy-2-(4-(1-methylpiperidin-4-yl)phenylamino)-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide
VTP-27999
2,5-bis(2-ethylhexyl)-3,6-di(thiophen-2-yl)pyrrolo[3,4-c]pyrrole-1,4(2H,5H)-dione
2-(methylthio)-4,6-bis(N-tert-butyloxy-carbonyl-piperidin-4-yloxy)pyrimidine
alpha-d-Glucopyranoside, beta-d-fructofuranosyl, dodecanoate
Falecalcitriol
C27H38F6O3 (524.2724989999999)
D018977 - Micronutrients > D014815 - Vitamins > D004100 - Dihydroxycholecalciferols D018977 - Micronutrients > D014815 - Vitamins > D006887 - Hydroxycholecalciferols D003879 - Dermatologic Agents
L-Proline, 1-(N2-(1-carboxy-3-phenylpropyl)-N6-((4-hydroxyphenyl)iminomethyl)-L-lysyl)-, (S)-
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
Guanadrel sulfate
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
Fedratinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EJ - Janus-associated kinase (jak) inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C172200 - JAK Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C125450 - JAK2 Inhibitor
22-[(2R)-1-hydroxy-3-phosphonooxypropan-2-yl]oxy-22-oxodocosanoic acid
(5Z)-5-[(2E)-2-[7a-methyl-1-[7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)heptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
C27H38F6O3 (524.2724989999999)
tert-butyl 4-ethyl-4-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamoyloxy]piperidine-1-carboxylate
C26H44N4O7 (524.3209833999999)
N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl-sn-glycero-3-phosphoethanolamine(1-)
(3S)-3beta-[2-(1,1-Dimethyl-2-propenyl)-1H-indole-3-ylmethyl]-6-(1,1-dimethyl-2-propenyl)-2,3,4,5aalpha,6,10b,11,11aalpha-octahydro-10balpha-hydroxy-1H-pyrazino[1,2:1,5]pyrrolo[2,3-b]indole-1,4-dione
N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(pyridin-3-ylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]oxane-4-carboxamide
1-[(4R,7R,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(3-methoxyphenyl)urea
1-[(4R,7R,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(3-methoxyphenyl)urea
1-[(4R,7S,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(3-methoxyphenyl)urea
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(pyridin-3-ylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]oxane-4-carboxamide
1-[(4S,7R,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(3-methoxyphenyl)urea
1-[(4S,7R,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(3-methoxyphenyl)urea
[3-Methyl-1-[3-methyl-1-oxo-1-(2,3,4,5,6-pentahydroxyhexoxy)pentan-2-yl]oxy-1-oxopentan-2-yl] 2-hydroxy-3-methylpentanoate
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
(1R)-2-(cyclopropylmethyl)-N-(2,4-difluorophenyl)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]carboxamide
3-cyclohexyl-1-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-9-(methanesulfonamido)-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methylurea
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[[(4-methoxyanilino)-oxomethyl]-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide
3-cyclohexyl-1-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-9-(methanesulfonamido)-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methylurea
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[[(4-methoxyanilino)-oxomethyl]-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide
3-cyclohexyl-1-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-9-(methanesulfonamido)-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methylurea
N-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
1-[(4S,7S,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(3-methoxyphenyl)urea
1-[(4R,7S,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(3-methoxyphenyl)urea
(2R)-4-amino-2-[3-[[(3R,5R,7S,8E,10E,12E)-3-amino-5-hydroxy-7-methoxyoctadeca-8,10,12-trienoyl]amino]propanoylamino]-4-oxobutanoic acid
C26H44N4O7 (524.3209833999999)
2-[[(2Z,5Z)-6-[[(2E,4E,10E)-7,9-dimethoxy-3,6,8-trimethyl-11-phenylundeca-2,4,10-trienoyl]amino]hexa-2,5-dienoyl]amino]acetic acid
[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-nonadec-9-enoate
(1-acetyloxy-3-phosphonooxypropan-2-yl) (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate
[1-[(2-acetyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (Z)-hexadec-9-enoate
C24H45O10P (524.2750199999999)
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (Z)-pentadec-9-enoate
C24H45O10P (524.2750199999999)
[1-[(2-butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (Z)-tetradec-9-enoate
C24H45O10P (524.2750199999999)
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-pentanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (Z)-tridec-9-enoate
C24H45O10P (524.2750199999999)
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (Z)-tridec-9-enoate
C24H45O10P (524.2750199999999)
[1-butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (Z)-tetradec-9-enoate
C24H45O10P (524.2750199999999)
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (Z)-pentadec-9-enoate
C24H45O10P (524.2750199999999)
[1-acetyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (Z)-hexadec-9-enoate
C24H45O10P (524.2750199999999)
1-(9Z-nonadecenoyl)-glycero-3-phospho-(1-sn-glycerol)
BIBS 39
BIBS 39 is a new nonpeptide angiotensin II (AII) receptor antagonist. Target: Angiotensin Receptor in vitro: BIBS 39 displaces [125I] AII from its specific binding sites with a Ki value of 29 ± 7 nM for the AII subtype 1 (AT1) receptor and a Ki value of 480 ± 110 nM for the AII subtype 2 (AT2) receptor. BIBS 222 shows a Ki value of 20 ± 7 nM for the AT1 subtype and a Ki value of 730 ± 170 nM for the AT2 subtype. BIBS 39 is 17 times more selective for the AT1 subtype and BIBS 222 37 times. BIBS 39 shifts the AII concentration-contractile response curves in isolated rabbit aorta to the right in a parallel fashion. [1] in vivo: In pithed rats, BIBS 39 dependently shifts the dose-response curve of AII to the right without affecting the maximal response. BIBS 222 also causes parallel shifts to the right but a significant reduction of the maximal responses was observed at 3 and 10 mg/kg i.v. These results show that the benzimidazole derivatives BIBS 39 is a potent and selective AII receptor antagonists. Substitution with a benzimidazole moiety results into a considerable loss of selectivity for the AT1 receptor subtype compared with an imidazole moiety as, for instance, in DuP 753.[1] BIBS 39 is a new nonpeptide angiotensin receptor blockers that has affinity for both AT1- and AT2-receptors, is also a potent antagonist of the cardiovascular effects of AII in pithed rabbits. [2]